Fortsæt til indhold

Makers of billion-dollar drugs set to face their first U.S. price negotiations

Brightly colored pharmaceutical medication, including antibiotics, paracetamol, Ibuprofen and cold relief tablets, manufactured by a variety of companies sit in this arranged photograph in London, U.K., on Friday, April 27, 2018. Pharmaceutical companies may see approval times cut to 14 months vs. 19 and about $370 million of sales brought forward per antibiotic after global regulators aligned rules to combat bacterial resistance. Bloomberg photo by Chris Ratcliffe
Bloomberg
John Tozzi & Nacha Cattan

Some of the most widely used drugs in the U.S. may be heading for lower prices under Medicare, a move that could save taxpayers billions of dollars and squeeze profits for big pharmaceutical companies.

The U.S. government is preparing to release a list this week of 10 drugs that the health program for the elderly will be able to negotiate prices for…

Artiklens emner
Bloomberg
Emner du følger